MEDICAL CHEMICAL DEFENSE (ATD)

Abstract

This project (TC3) supports the advanced development of medical countermeasures to include prophylaxes, pretreatments, antidotes, skin decontaminants and therapeutic drugs against identified and emerging chemical warfare threat agents. Analytical stability studies, safety and efficacy screening, and preclinical toxicology studies are performed prior to full-scale development of promising pretreatment or treatment drug compounds. Entry of candidate pretreatment/prophylaxes, therapeutics, and diagnostic technologies into advanced development (i.e., efforts funded in Budget Activities 4 and 5) is facilitated by the development of technical data packages that support the Food and Drug Administration (FDA) Investigational New Drug (IND) application and licensure processes, as well as Department of Defense (DoD) acquisition regulations. Categories for this project include Pretreatments, Diagnostics, and Therapeutics to address Chemical Warfare Agent (CWA) and Non-Traditional Agents (NTAs) exposure. In FY13, all non-NTA research in this Project (TC3) was re-aligned to Project TM3 - Techbase Medical Defense (ATD). All NTA-dedicated research in this Project was re-aligned to Project NT3 - Techbase Non-Traditional Agents Defense (ATD).

Open PDF

Document Details

Document Type
Project
Publication Date
Oct 01, 2014
Source ID
TC3_0603384BP_3_0400_PB_2014

Tags

Readers

  • Critical Infrastructure Protection in CBRN and WMD Threats.

Related Documents